top of page
Migraine in Adolescents (12-17 years)

Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age

Wave
  • Facebook Social Icon
  • Instagram Social Icon

© 2019 by Genoma Research Group

bottom of page